Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 3/20 | 0.36 |
| ▸ | AKT2 | P31751 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249014 | 0.90 | PDE10A (0.35) | AKT1AKT2PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10249146 | 0.88 | HASPIN (0.35) | AKT1AKT2PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10248971 | 0.87 | PDE10A (0.36) | AKT1AKT2PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10284542 | 0.87 | POLB (0.46) | PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10249153 | 0.87 | SMN1; SMN2 (0.36) | AKT1AKT2PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10252628 | 0.87 | PDE10A (0.35) | AKT1AKT2PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10252611 | 0.87 | PDE10A (0.35) | AKT1AKT2PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10249155 | 0.86 | HTT (0.37) | AKT1AKT2PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10249007 | 0.83 | POLB (0.36) | AKT1AKT2PDE10APOLBSMN1; SMN2 | |
| SCHEMBL10249282 | 0.83 | TSHR (0.36) | AKT1AKT2PDE10APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-07-12 | — | — | US | disclosed |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178779-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | AKT1 1153/4885AKT2 2245/4885PDE10A 4112/4885 |
| US-20120015975-A1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | C3AR1, C9, C5 | AKT1 1153/4885AKT2 2245/4885PDE10A 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.